Health-Related Quality of Life over Time in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide and Dexamethasone Until Progression

Dan T. Vogl,1 Michelle DelFonso,2 Kevin Song,2 Shien Guo,3 Craig J. Gibson,4 Annette Ervin-Haynes,5 Thierry Fascom6

1Wesleyan Cancer Center, University of Pennsylvania, Philadelphia, PA; 2Universitair Ziekenhuis Leuven, Campus, Leuven, Belgium; 3Vancouver General Hospital, Vancouver, BC, Canada; 4Evidera, Lexington, MA; 5Celgene Corporation, Summit, NJ; 6Hôpital Claude Huriez, Lille, France

INTRODUCTION

The first 18 months of treatment in the FIRST trial, an improvement in HQoL was seen in patients receiving Rd. HRQoL data were not collected past 18 months. Therefore, we sought to estimate HRQoL during extended Rd therapy, using data points that were collected beyond 18 months.

OBJECTIVE

To examine changes in HRQoL in transplant-ineligible patients with NDMM during continuous Rd therapy beyond 18 months by identifying predictors of HRQoL questionnaire scores.

METHODS

Study Design

The FIRST trial is a multicenter, open-label, 3-arm randomized phase 3 trial designed to compare the safety and efficacy of Rd (Rd) or MPT (MPT) or Rd (Rd) treatment with the Eastern Cooperative Oncology Group performance status

RESULTS

Predictors of Change in HRQoL Scores Over Time (Table 1)

Table 1. Key Time-Varying Predictors of Change in HRQoL Scores

Conclusions

The analysis is exploratory in nature; further research is needed to

ACKNOWLEDGEMENTS

The authors acknowledge the contributions of the investigators, sites, and patients involved in this study. Celgene Corporation provided financial support for this study. The authors received additional assistance from Kristina Hernandez, PhD and Peter J. Simon, PhD, and printing support from MedTech Media, sponsored by Celgene Corporation.

DISCLOSURES

D.V. reports consulting or advisory for Millennium/Takeda, Celgene, Amgen/Onyx, and Janssen; research funding from Millennium/Takeda, Foundation Medicine, Compendex, and GSK; and employee and stock ownership from Celgene. K.S. reports honoraria and advisory for Janssen, Celgene Corporation, and Takeda and research funding from Millennium/Takeda, Foundation Medicine, and GSK; and employee and stock ownership from Celgene. P.J.S. reports consulting or advisory for Celgene, Janssen, Millennium, Onyx, and Bristol-Myers Squibb and employee from Celgene. T.F. has served as a member of the boards of directors or advisory committees for Amgen, Celgene, Millennium, Onyx, and Biogen Idec and has received honoraria from Celgene. C.G. and A.E.H. report employment and stock ownership from Celgene. M.D. reports honoraria and consulting/advisory for Amgen, Janssen, and Pﬁzer; and grants/research support from Celgene.

REFERENCES


CORRESPONDENCE

Dan T. Vogl: dan.vogl@uphs.upenn.edu

Presented at the ASCO 2016 Annual Meeting, June 3-7, Chicago, Illinois